Haleon plc (HLN)vsINC Research Holdings Inc (INCR)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
INCR
INC Research Holdings Inc
$0.75
-2.58%
HEALTHCARE · Cap: $42.31M
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 4437% more annual revenue ($11.03B vs $243.12M). HLN leads profitability with a 15.1% profit margin vs -29.2%. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
INCR
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Intrinsic value data unavailable for INCR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
3.4% revenue growth
Smaller company, higher risk/reward
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : INCR
The strongest argument for INCR centers on Price/Book.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : INCR
The primary concerns for INCR are Revenue Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
HLN profiles as a value stock while INCR is a turnaround play — different risk/reward profiles.
INCR carries more volatility with a beta of 0.29 — expect wider price swings.
INCR is growing revenue faster at 3.4% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 32/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →INC Research Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?